Group 1 - Core viewpoint: Wuhan Heyuan Biotechnology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking it as one of the first newly registered companies in the growth tier [1] - On its first trading day, Heyuan Biotechnology closed at 91.10 yuan, representing a 213.49% increase, and by October 31, the stock price reached 123.55 yuan per share, with a total market capitalization exceeding 40 billion yuan [1] - The company raised a total of 2.6 billion yuan through this issuance, primarily for the construction of a recombinant human albumin industrialization base, new drug research and development, and to supplement working capital [1] Group 2 - Heyuan Biotechnology, established in 2006, is an innovative enterprise that has developed a recombinant human albumin injection (from rice) called Aofumin, which is the world's first "rice-derived" innovative drug approved by the National Medical Products Administration [1] - The company has built an intelligent production line with an annual capacity of 1 million bottles that meets international standards and is currently constructing an industrialization base with an expected annual output of 12 million bottles of recombinant human serum albumin injection, aiming for completion by 2026 [1] Group 3 - Shareholder information indicates that Shuangliang Energy's controlling shareholder, Shuangliang Group, holds shares in Heyuan Biotechnology through its investment platform, Shanghai Shuangliang Equity Investment Co., Ltd. [2] - Among the shareholders holding more than 5% of the company, Yang Daichang and Su Xueteng act in concert, while Beida Pharmaceutical and Hangzhou Beiming collectively hold 9.02% of the shares [2] - Shanghai Tongsheng and Shanghai Shuangliang together hold 7.63% of the shares, with Ye Jiping holding 6.45%, and Yifeng Ruiyi and Yifeng No. 9 collectively holding 5.31% [2]